Patents by Inventor Hsun-Lang Chang

Hsun-Lang Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9222072
    Abstract: The present invention relates to a manufacturing method of immune killer cells characterized in that an immune killer cell is induced in a culture medium containing concanavalin A (ConA), and the immune killer cell is maintained or expanded in a culture procedure. Antibody proteins are not used as a stimulant in the culture process to avoid the risk of being infected by zoonotic diseases and effectively increase the number and specific release of the immune killer cells.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: December 29, 2015
    Assignee: IVY LIFE SCIENCES CO., LTD.
    Inventor: Hsun-Lang Chang
  • Publication number: 20110201114
    Abstract: The present invention relates to a manufacturing method of immune killer cells characterized in that an immune killer cell is induced in a culture medium containing concanavalin A (ConA), and the immune killer cell is maintained or expanded in a culture procedure. Antibody proteins are not used as a stimulant in the culture process to avoid the risk of being infected by zoonotic diseases and effectively increase the number and specific release of the immune killer cells.
    Type: Application
    Filed: February 9, 2011
    Publication date: August 18, 2011
    Inventor: Hsun-Lang CHANG
  • Patent number: 7507532
    Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: March 24, 2009
    Assignee: Medigen Biotechnology Corporation
    Inventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho
  • Publication number: 20080305188
    Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.
    Type: Application
    Filed: April 3, 2003
    Publication date: December 11, 2008
    Inventors: Hsun-Lang Chang, Wu-Chang Chuang, Wei-Ying Kuo, Guang-Tzuu Shane, Hung-Sheng Chang
  • Publication number: 20080119567
    Abstract: The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same composition is shown to be able to eradicate H. pylori in vitro. The invention also relates to a composition comprising citronellol and extracts from roots of Sophora plants. The present invention further relates to the use of citronellol to inhibit gastric ulcers. The invention also relates to the use of the same composition to inhibit the enzymatic activity of Na+/K+-ATPase to strengthen heart muscle contractions and prevent heart failure.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 22, 2008
    Inventors: Andy A.T. Fong, Guang-Tzuu Shane, Hsun-Lang Chang, Wei-Ying Kuo
  • Publication number: 20070166404
    Abstract: The present invention relates to a novel composition comprising geranium oil and extracts from the roots of the plants of the genus Sophora, preferably Sophora tonkinesis. Said composition can be administered to mammalian animals undergoing cancer treatments, such as chemotherapy and radiation therapy, that would induce the side effect of bone marrow suppression. The administration can be made before, during and or after the cancer treatment.
    Type: Application
    Filed: April 3, 2003
    Publication date: July 19, 2007
    Inventors: Hsun-Lang Chang, Wu-Chang Chuang, Wei-Ying Kuo, Guang-Teuu Shane, Hung-Sheng Chang
  • Publication number: 20060068411
    Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.
    Type: Application
    Filed: March 7, 2005
    Publication date: March 30, 2006
    Applicant: Medigen Biotechnology Corporation
    Inventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li, Chih-Ping Hsu, Pei-Hsun Ho
  • Publication number: 20050153352
    Abstract: MG20 (CCNDBP1) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MG20 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MG20 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MG20 expression or activity, thereby treating cancer, in vivo.
    Type: Application
    Filed: January 7, 2005
    Publication date: July 14, 2005
    Inventors: Stanley Chang, Hsun-Lang Chang, Wei-Ying Kuo, Kuo-Yen Chen, Ning-Yi Li